araag2/HINT huggingface dataset:
Clinical trial NCT02484547 (phase 3, status: terminated)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: aducanumab (biib037), aducanumab (biib037), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    study was discontinued based on futility analysis done and not based on safety concerns.
    follow-up visits and closing out study activities are completed
  
Eligibility criteria:

        Key Inclusion Criteria:

          -  Must meet all of the following clinical criteria for MCI due to AD or mild AD and must
             have:

          -  A Clinical Dementia Rating (CDR)-Global Score of 0.5.

          -  Objective evidence of cognitive impairment at screening

          -  An MMSE score between 24 and 30 (inclusive)

          -  Must have a positive amyloid Positron Emission Tomography (PET) scan

          -  Must consent to apolipoprotein E (ApoE) genotyping

          -  If using drugs to treat symptoms related to AD, doses must be stable for at least 8
             weeks prior to screening visit 1

          -  Must have a reliable informant or caregiver

        Key Exclusion Criteria:

          -  Any medical or neurological condition (other than Alzheimer's Disease) that might be a
             contributing cause of the subject's cognitive impairment

          -  Have had a stroke or Transient Ischemic Attack (TIA) or unexplained loss of
             consciousness in the past 1 year

          -  Clinically significant unstable psychiatric illness in past 6 months

          -  History of unstable angina, myocardial infarction, advanced chronic heart failure, or
             clinically significant conduction abnormalities within 1 year prior to Screening

          -  Indication of impaired renal or liver function

          -  Have human immunodeficiency virus (HIV) infection

          -  Have a significant systematic illness or infection in past 30 days

          -  Relevant brain hemorrhage, bleeding disorder and cerebrovascular abnormalities

          -  Any contraindications to brain magnetic resonance imaging (MRI) or PET scans

          -  Alcohol or substance abuse in past 1 year

          -  Taking blood thinners (except for aspirin at a prophylactic dose or less)

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Clinical trial NCT02485067 (phase 3, status: completed)
Conditions: overactive bladder
ICD codes: N32.81
Drugs: thvd-201, placebo(for thvd-201), detrusitol 2mg tablet, placebo(for detrusitol 2mg tablet)
SMILES: CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C, CC(C)N(CC[C@H](C1=CC=CC=C1)C1=C(O)C=CC(C)=C1)C(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  20 - 85 years

          -  History of OAB (pure urge or mixed urinary incontinence with predominant urge
             incontinence) for ≥ 6 months.

          -  In the case of females, at least 2 years has passed since menopause. Or all
             pre-menopausal female subjects must have been using a highly effective method of birth
             control during the study. Subject of childbearing potential must have had a negative
             pregnancy test prior to enrollment.

        Exclusion Criteria:

          -  Predominate stress incontinence, insensate incontinence (those incapable of
             distinguishing discrete incontinence episodes) and overflow incontinence, as major
             reason for urine loss or urinary frequency as determined by the investigator.

          -  History of neurogenic bladder.

          -  PVR > 200mL

          -  History of clinically significant renal disease or estimated creatinine clearance
             defined by Cockcroft and Gault formula < 30 mL/min.

          -  History of malignant tumor within the past 5 years.

          -  History or presence of tachyarrhythmia or cardiac disease that in the opinion of the
             investigator might have confounded the results of the study or posed additional risk
             to the subject. Subjects who had a value for QTc > 450 msec at the Screening visit.

          -  Patient with asthma

          -  PSA ≥ 10 ng/mL in male who is 50 years and over.
Clinical trial NCT02486198 (phase 3, status: completed)
Conditions: neurotoxicity
ICD codes: G92.00, G92.01, G92.02, G92.03, G92.04, G92.05
Drugs: placebo, gm, oxaliplatin-based chemotherapy
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          1. Patients shall have normal organic function such as liver function, Cardiac function
             and renal function;

          2. male or female age >18 years old;

          3. diagnosis GI cancer with histology;

          4. Chronic neurotoxicity grade is 2 or more

          5. Karnofsky Performance scores should be 80 or more

          6. patients are in oxaliplatin-based chemotherapy courses or no more than 21 days after
             last oxaliplatin usage for patients who will discontinue oxaliplatin usage.

          7. without uncured tumor except GI cancer,

          8. Patients should be expected to live no shorter than 3 months

        Exclusion Criteria:

          1. patients who is receiving anti-neurotoxicity treatment;

          2. WBC<4.0×109/L，ANC<1.5×109/L,PLT<100×109/L，Hb<90g/L,TBIL>1.5Limitation;BUN）>1.5Limitati
             on；Cr）>1.5Limitation；ALT or AST>2.5Limitation（without liver metastasis）；ALT or
             AST）>5Limitation（with liver metastasis）;

          3. heart dysfunction;

          4. brain metastasis with symptoms;

          5. peripheral nervous system or central nervous system abnormal including diabetes
             mellitus patients with neuropathy;

          6. in situation of oxaliplatin-based chemotherapy progressed, the next chemotherapy
             regime should not contain agents which will cause neurotoxicity (such as paclitaxel
             and cisplatin)
Clinical trial NCT02487030 (phase 3, status: completed)
Conditions: hepatitis c virus infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: ldv/sof, rbv
SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Willing and able to provide written informed consent

          -  Chronic HCV infection (≥ 6 months) documented by medical history or liver biopsy

          -  HCV genotype 4 at screening

          -  HCV treatment naive or prior participation in this study or study GS-US-334-0138
             (Cohorts 1 and 2 only)

          -  Cohort 3 only: HCV treatment-experienced (previously received therapy for HCV
             infection with an interferon (IFN)-containing regimen, with or without RBV and/or an
             HCV NS3/NS4A protease inhibitor (PI)

          -  Body mass index (BMI) ≥ 18 kg/m^2

          -  Screening laboratory values within defined thresholds

          -  Use of effective protocol-approved contraception methods

        Key Exclusion Criteria:

          -  History of clinically-significant illness or any other major medical disorder that may
             interfere with treatment, assessment or compliance with the protocol

          -  Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

          -  Pregnant or nursing females or male with pregnant female partner

          -  Clinically-relevant drug or alcohol abuse within 12 months of screening

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT02487446 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: qva149, umeclidinium/vilanterol, placebo (umeclidinium/vilanterol), placebo (qva149)
SMILES: C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC1=C(Cl)C=CC=C1Cl, OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC1=C(Cl)C=CC=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female adults aged ≥40 yrs

          -  Smoking history of at least 10 pack years

          -  Diagnosis of stable Chronic Obstructive Pulmonary Disease (COPD) as classified by the
             Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2015)

          -  Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)< 80% and ≥ 30% of the
             predicted normal value and post-bronchodilator FEV1/FVC (forced vital capacity) <70%

          -  Modified Medical Research Council questionnaire grade of 2 or higher

        Exclusion Criteria:

          -  Patients who have had a respiratory tract infection within 4 weeks prior to Visit 1

          -  Patients with concomitant pulmonary disease

          -  Patients with a history of asthma

          -  Any patient with lung cancer or a history of lung cancer

          -  Patients with a history of certain cardiovascular co-morbid conditions

          -  Patients with a known history and diagnosis of alpha-1 antitrypsin deficiency

          -  Patients in the active phase of a supervised pulmonary rehabilitation program

          -  Patients contraindicated for inhaled anticholinergic agents and β2 agonists

          -  Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT02487498 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: qva149, umeclidinium/vilanterol, placebo (umeclidinium/vilanterol ), placebo (qva149)
SMILES: C[N+]1(C)CCC(C1)OC(=O)C(O)(C1CCCC1)C1=CC=CC=C1, OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC1=C(Cl)C=CC=C1Cl, OCC1=C(O)C=CC(=C1)[C@@H](O)CNCCCCCCOCCOCC1=C(Cl)C=CC=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female adults aged ≥40 yrs

          -  Smoking history of at least 10 pack years

          -  Diagnosis of stable Chronic Obstructive Pulmonary Disease (COPD) as classified by the
             Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2015)

          -  Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)< 80% and ≥ 30% of the
             predicted normal value and post-bronchodilator FEV1/FVC (forced vital capacity) <70%

          -  Modified Medical Research Council questionnaire grade of 2 or higher

        Exclusion Criteria:

          -  Patients who have had a respiratory tract infection within 4 weeks prior to Visit 1

          -  Patients with concomitant pulmonary disease

          -  Patients with a history of asthma

          -  Any patient with lung cancer or a history of lung cancer

          -  Patients with a history of certain cardiovascular co-morbid conditions

          -  Patients with a known history and diagnosis of alpha-1 antitrypsin deficiency

          -  Patients in the active phase of a supervised pulmonary rehabilitation program

          -  Patients contraindicated for inhaled anticholinergic agents and β2 agonists

          -  Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT02488525 (phase 3, status: terminated)
Conditions: heart failure
ICD codes: I50.814, I09.81, I50.82, I50.89, I50.9, T86.22, I11.0
Drugs: prophylactic treatment with wilfactin
SMILES: COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1
Reason stopped: 
    deficient inclusion
  
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients > 18 years who need a CF-LVAD due to advanced heart failure.

          -  Functional defects of VWF measured between day 2 and day 4 after implantation (either
             PFA-ADP closure time >180 sec and or VWF:Act/VWF:Ag≤ 0.7)

          -  Informed consent of the patient or support person in case of disability at baseline
             (patient intubated and ventilated)

        Exclusion Criteria:

          -  Treatment with Wilfactin® within the last seven days

          -  Previous adverse reaction to Wilfactin®

          -  Absence of functional defects of VWF measured between day 2 and day 4 after
             implantation (either PFA-ADP closure time >250 sec and or VWF:Act/VWF:Ag<0.7)

          -  Patient with a known thrombophilia

          -  Patient with a known severe bleeding disorder

          -  Patient refusal or environment

          -  Minor patients

          -  Pregnant women
Clinical trial NCT02489227 (phase 3, status: completed)
Conditions: plaque psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: chs-1420, adalimumab
SMILES: O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female adults

          -  PsO diagnosis for 6 months

          -  Active disease: PASI greater than or equal to 12, Physician's Static Global Assessment
             (PSGA) score greater than or equal to 3 (based on a scale of 0-5),

          -  Body Surface Area (BSA) involved with PsO greater than or equal to 10%

        Exclusion Criteria:

          -  Forms of psoriasis other than PsO

          -  Drug induced psoriasis

          -  Positive QuantiFERON-tuberculosis (TB) Gold Test

          -  Presence of significant comorbid conditions

          -  Chemistry and hematology values outside protocol specified range

          -  Major systemic infections
Clinical trial NCT02489318 (phase 3, status: active, not recruiting)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: apalutamide, placebo, androgen deprivation therapy (adt)
SMILES: CNC(=O)C1=CC=C(C=C1F)N1C(=S)N(C(=O)C11CCC1)C1=CC(=C(N=C1)C#N)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of prostate adenocarcinoma as confirmed by the investigator

          -  Metastatic disease documented by greater than or equal to (>=) 1 bone lesions on 99mTc
             bone scan. Participants with a single bone lesion must have confirmation of bone
             metastasis by computed tomography (CT) or magnetic resonance imaging (MRI)

          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) grade of 0 or 1

          -  Participants who received docetaxel treatment must meet the following criteria: a)
             Received a maximum of 6 cycles of docetaxel therapy for mHSPC; b) Received the last
             dose of docetaxel <=2 months prior to randomization; c) Maintained a response to
             docetaxel of stable disease or better, by investigator assessment of imaging and PSA,
             prior to randomization

          -  Other allowed prior treatment for mHSPC: a) Maximum of 1 course of radiation or
             surgical intervention; radiation therapy for metastatic lesions must be completed
             prior to randomization; b) Less than or equal to (<=) 6 months of ADT prior to
             randomization

          -  Allowed prior treatments for localized prostate cancer (all treatments must have been
             completed >= 1 year prior to randomization) a) <= 3 years total of ADT; b) All other
             forms of prior therapies including radiation therapy, prostatectomy,lymph node
             dissection, and systemic therapies

        Exclusion Criteria:

          -  Pathological finding consistent with small cell, ductal or neuroendocrine carcinoma of
             the prostate

          -  Known brain metastases

          -  Lymph nodes as only sites of metastases

          -  Visceral (ie, liver or lung) metastases as only sites of metastases

          -  Other prior malignancy less than or equal to 5 years prior to randomization with the
             exception of squamous or basal cell skin carcinoma or non-invasive superficial bladder
             cancer

          -  Prior treatment with other next generation anti-androgens or other CYP17 inhibitors,
             immunotherapy or radiopharmaceutical agents for prostate cancer

          -  History of seizures or medications known to lower seizure threshold
Clinical trial NCT02489968 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: empagliflozin 10 mg + linagliptin 5 mg, empagliflozin 10 mg, empagliflozin 25 mg + linagliptin 5 mg, empagliflozin 25 mg, placebo
SMILES: CN(C)C(=N)NC(N)=N, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN(C)C(=N)NC(N)=N, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  Diagnosis of type 2 diabetes prior to informed consent

          -  Male and female patients on diet and exercise regimen for at least 12 weeks prior to
             informed consent who are:

               -  drug-naïve, defined as no antidiabetic drugs for at least 12 weeks prior to
                  informed consent or,

               -  pre-treated with one oral antidiabetic drug (for sulfonylurea, with up to half of
                  the maximum approved dose) on stable dosage for at least 12 weeks prior to the
                  informed consent (for thiazolidinedione, therapy has to be unchanged for at least
                  18 weeks prior to the informed consent). Individual antidiabetic drug will have
                  to be discontinued at Visit 1.

          -  haemoglobin A1c (HbA1c) at Visit 1 (screening)

               -  for patients without antidiabetic therapy : HbA1c >=8.0 to =<10.5%

               -  for patients with one oral antidiabetic drug : HbA1c >=7.5 to =<10.5%

          -  HbA1c >=7.5 to =<10.0% at Visit 4 for randomisation into the double blind treatment
             period

        Exclusion criteria:

          -  Uncontrolled hyperglycaemia with a glucose level >270 mg/dL (>15.0 mmol/L) during the
             open label stabilisation period and placebo run in period

          -  Impaired renal function, defined as estimated glomerular filtration rate (eGFR) <45
             mL/min/1.73m2 (modification of diet in renal disease (MDRD) formula)

          -  Acute coronary syndrome, stroke or transient ischemic attack (TIA) within 12 weeks
             prior to informed consent

          -  Indication of liver disease, defined by serum levels of either alanine transaminase
             (ALT), aspartate transaminase (AST), or alkaline phosphatase (ALP) above 3 x upper
             limit of normal (ULN)
Clinical trial NCT02492620 (phase 3, status: completed)
Conditions: chronic kidney disease, hyperphosphatemia, iron deficiency anemia, renal insufficiency
ICD codes: I12.9, N18.9, I12.0, D63.1, N18.1, N18.5, I13.0, D50.9, D50.0, D50.8, N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, Q60.1
Drugs: ferric citrate
SMILES: [Fe+3]
Eligibility criteria:

        Inclusion Criteria:

          1. Age >18 years at screening visit

          2. Serum phosphate > or equal to 3.0 mg/dL obtained at screening

          3. CKD with eGFR < or equal to 20 mL/min obtained at screening*

          4. Hemoglobin (Hgb) >8.0 g/dL obtained at screening

          5. TSAT <55% obtained at screening

          6. Females of child bearing potential with negative serum pregnancy test obtained at
             screening

          7. Willing and able to give written informed consent

          8. Anticipated to have > or equal to 8 weeks prior to need for initiating RRT in the
             opinion of the investigator

        Exclusion Criteria:

          1. Liver enzymes (ALT/AST) >X3 times upper limit of normal at screening

          2. Use of IV iron, blood transfusions or ESA agents within 2 weeks prior to the screening
             visit and prior to the Day 1 visit.

          3. Evidence of acute kidney injury (i.e., no CKD) or planned need for RRT within 12 weeks
             of screening

          4. Scheduled kidney transplant within 24 weeks of screening

          5. Contra-indication to ferric citrate: iron overload syndrome, allergic reaction or
             known intolerance to ferric citrate

          6. Clinically significant medical condition felt to interfere with tolerance of oral
             medication

          7. Life expectancy < 6 months or confirmed conviction that subject does NOT want to
             initiate RRT despite a decline in kidney function

          8. Active drug or alcohol dependence or abuse (excluding tobacco use or marijuana use)
             within the 12 months prior to screening (in the opinion of the PI)

          9. Psychiatric disorder that interferes with the subject's ability to comply with the
             study protocol in the opinion of the PI

         10. Any other medical condition that, in the opinion of the PI, renders the subject unable
             to or unlikely to complete the trial or that would interfere with optimal
             participation in the trial or produce significant risk to the subject

         11. Inability to cooperate with study personnel or study procedures

         12. Females who are pregnant or breastfeeding

         13. Receiving or has received any investigational drug with in the past 30 days prior to
             the Day 1 visit
Clinical trial NCT02493452 (phase 3, status: completed)
Conditions: irritable bowel syndrome characterized by constipation
ICD codes: B09, B08.8
Drugs: plecanatide, placebo
SMILES: [H][C@](C)(O)[C@]1([H])N=C(O)[C@]2([H])CSSC[C@]([H])(N=C(O)[C@]([H])(CCC(O)=O)N=C(O)[C@]([H])(CC(O)=O)N=C(O)[C@@]([H])(N)CC(O)=N)C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CSSC[C@]([H])(N=C(O)CN=C1O)C(O)=N[C@@]([H])(CC(C)C)C(O)=O)C(O)=N[C@@]([H])(C(C)C)C(O)=N[C@@]([H])(CC(O)=N)C(O)=N[C@@]([H])(C(C)C)C(O)=N[C@@]([H])(C)C(O)=N2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        • Adult patients between the ages of 18 and 85 years (inclusive) with a diagnosis of IBS
        based on ROME III diagnostic criteria and meeting criteria for diagnosis of the
        constipation predominant subtype - IBS-C

        Exclusion Criteria:

          -  Refusal or inability to sign informed consent for the trial

          -  Refusal or inability to complete daily Episodic (real-time) BM / RM calls, End of Day
             daily Calls, and/or complete electronic questionnaires

          -  BMI ≥ 40 or < 18

          -  Women of child bearing potential who refuse to use an acceptable method of birth
             control for the duration of the trial

          -  Women who are pregnant or lactating

          -  Diagnosis of IBS-D or IBS-M

          -  Organic or obstructive disease of the small or large intestine

          -  Use of laxatives other than the study-supplied rescue medication (Dulcolax®,
             bisacodyl)

          -  Use of a prohibited concomitant medication within the time frame prior to screening
             outlined in the study protocol for that medication

          -  Unstable medical illness

          -  Bilirubin > 3X ULN in the absence of a conjugation defect

          -  Any laboratory value > 3X ULN unless discussed and approved by the study Medical
             Monitor